Management of HIV Positive Patients with Undetectable Viral Load

Laboratory Monitoring Recommendations

HIV RNA viral load should be monitored every 3 months until <50 copies/mL for 1 year, then every 6 months as long as suppression is maintained, according to the American Medical Association 1
CD4 cell count should be monitored every 6 months until >250/μL for 1 year, then can be discontinued as long as viral suppression is maintained, as recommended by the American Medical Association 1
Safety testing, including comprehensive metabolic panel and complete blood count, should be performed regularly to monitor for medication side effects, as suggested by the American Medical Association 1
Co-infection screening, such as for STIs, tuberculosis, and hepatitis, should be performed periodically, as recommended by the American Medical Association 1

Undetectable viral load indicates successful viral suppression, which is the primary goal of antiretroviral therapy, according to the American Medical Association and the American College of Physicians 2, 3

Abacavir Sulfate-Lamivudine 600/300 mg is an appropriate backbone regimen for HIV treatment, as recommended by the American Medical Association 2, 4
With undetectable viral load, the current regimen is effectively suppressing viral replication, which is the primary goal of therapy, according to the American College of Physicians and the American Medical Association 3, 5
There is no indication to change the current regimen based on low CD4/CD8 ratio alone when viral suppression is maintained, as stated by the American Medical Association 5

Review the patient's complete ART history, regimen tolerability, co-medications, and prior resistance testing before considering any changes, as recommended by the American Medical Association 5
If the patient is experiencing any side effects from the current regimen, consider alternative options, such as Dolutegravir/lamivudine or Tenofovir alafenamide (TAF)-based regimens, as suggested by the American Medical Association 4, 5

Ensure HLA-B*5701 testing was performed before initiating abacavir to prevent hypersensitivity reactions, as recommended by the American Medical Association 4
If the patient has hepatitis B virus co-infection, maintain lamivudine in the regimen as it provides activity against HBV, according to the American Medical Association 5

There is currently no specific intervention recommended solely to address low CD4/CD8 ratio when viral suppression is maintained, as stated by the American College of Physicians and the American Medical Association 3, 5

Continue regular monitoring of viral load to ensure continued suppression, as recommended by the American Medical Association 1
Monitor CD4 counts and CD4/CD8 ratio to track immunological recovery, according to the American Medical Association 1
Assess for clinical manifestations of immune dysfunction despite viral suppression, as suggested by the American College of Physicians 3